Zepbound belongs to a class of medications known as dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists. These hormones naturally participate in regulating appetite, digestion, and glucose metabolism.
Tirzepatide activates both GIP and GLP-1 receptors, influencing several processes associated with eating behaviour and metabolic regulation. Its effects on appetite include changes in hunger signals, food consumption, and the feeling of satisfaction after meals.
The medication supports appetite regulation through several mechanisms:
Reduced hunger: Zepbound influences appetite-related pathways that can decrease feelings of hunger.
Increased fullness: It helps individuals experience a greater sense of fullness after eating.
Slower gastric emptying: Tirzepatide delays the movement of food from the stomach into the small intestine, particularly during the initial stages of treatment.
Reduced food intake: Changes in appetite and fullness may help reduce overall calorie consumption.
Blood sugar regulation: It improves glucose-dependent insulin secretion and reduces glucagon secretion when appropriate.
These effects work together to influence eating patterns and support weight management. Individual responses can vary depending on factors such as dosage, medical history, lifestyle, and treatment duration.
Zepbound is administered as a once-weekly subcutaneous injection. Treatment generally begins with a 2.5 mg dose once weekly for four weeks. This starting dose helps the body adjust to the medication and is not intended as a maintenance dose.
After the initial four weeks, the dosage is generally increased to 5 mg once weekly. Depending on individual response and tolerability, a healthcare professional may gradually increase the dosage in 2.5 mg increments after at least four weeks at the current dose.
The approved maintenance doses for chronic weight management are 5 mg, 10 mg, and 15 mg once weekly. The maximum recommended dosage is 15 mg per week.
Potential benefits of Zepbound include:
Supporting long-term weight management in eligible adults.
Helping reduce appetite and overall food intake.
Improving feelings of fullness after meals.
Supporting improvements in certain weight-related metabolic measurements.
Helping manage moderate-to-severe obstructive sleep apnea in adults with obesity.
Possible side effects include:
Nausea and vomiting.
Diarrhea or constipation.
Abdominal discomfort and stomach pain.
Decreased appetite.
Indigestion and acid reflux.
Injection-site reactions.
Fatigue in some individuals.
Zepbound also carries important warnings. It has a boxed warning regarding thyroid C-cell tumors observed in animal studies. It should not be used by individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Other serious risks include pancreatitis, gallbladder problems, kidney injury associated with dehydration, and severe gastrointestinal reactions.
Healthcare professionals assess medical history, existing medications, treatment response, and potential risks before prescribing Zepbound. Regular monitoring helps evaluate tolerability, dosage requirements, and changes in weight-related health conditions.